EO 14155 Act of 2025

House Bill

H.R. 3839

119th Congress

EO 14155 Act of 2025

In Committee

Introduced:Jun 9, 2025

Primary Sponsor

Chrissy Houlahan

Representative

Democratic

PA-6

Cosponsors

1

Quick Stats

Policy Area

Health

Summary

This bill would require the FDA to provide more information to generic drug companies about how their products compare to brand-name drugs. This could help generic companies better understand the FDA's approval process and make more effective generic drugs.

Latest Action

Referred to the Subcommittee on Health.

SponsorChrissy Houlahan (D-PA)

Introduced6/9/2025

StatusReferred to the Committee on Foreign Affairs, and in addition to the Committees on Armed Services, I

ChamberHouse

Data from Congress.gov

See this page through your district lens

Enter ZIP to personalize representatives and vote context.

Stay on top of this issue

Subscribe for weekly bill and representative updates.

Vote Prediction

EO 14155 Act of 2025

This bill would require the FDA to provide more information to generic drug companies about how their products compare to brand-name drugs. This could help generic companies better understand the FDA's approval process and make more effective generic drugs.

Community Breakdown

Pass

0%

Fail

0%

0 predictions

This bill would require the FDA to provide more information to generic drug companies about how their products compare to brand-name drugs. This could help generic companies better understand the FDA's approval process and make more effective generic drugs.

Bill Number: 3839
Sponsor: Chrissy Houlahan (D-PA)
Introduced: 6/9/2025
Status: Referred to the Committee on Foreign Affairs, and in addition to the Committees on Armed Services, I
Policy Area: Health

Data from Congress.gov

AI-generated summary

Fact Sheet

Title: EO 14155 Act of 2025
Bill Number: 3839
Sponsor: Chrissy Houlahan (D-PA)
Status: Referred to the Committee on Foreign Affairs, and in addition to the Committees on Armed Services, I
Introduced: 6/9/2025
Summary: This bill would require the FDA to provide more information to generic drug companies about how their products compare to brand-name drugs. This could help generic companies better understand the FDA's approval process and make more effective generic drugs.

Data from Congress.gov

AI Summary

Plain-English explanation of this bill

This bill would require the FDA to provide more information to generic drug companies about how their products compare to brand-name drugs. This could help generic companies better understand the FDA's approval process and make more effective generic drugs.

Last updated: 12/30/2025

Official Summary

Congressional Research Service summary

<p></p> <p>This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.</p>

Key Points

Main provisions of the bill

The FDA would have to inform generic drug companies if their product is the same as the brand-name drug, and explain why if it's not.
The FDA would have to update or publish guidance on how it makes these determinations about generic drug similarities.
This could help generic drug companies develop products that are more likely to be approved, increasing competition and potentially lowering drug prices.

How This Impacts Americans

Potential effects on citizens and communities

If this bill becomes law, it would primarily impact generic drug companies, who would get more transparency from the FDA about the approval process. This could help them bring more affordable generic drugs to market, benefiting consumers who rely on lower-cost medications.

Policy Areas

Primary Policy Area

Health

Related Subjects

Administrative law and regulatory procedures

Department of Health and Human Services

Drug safety, medical device, and laboratory regulation

Prescription drugs

Scope & Jurisdiction

Jurisdiction Level

federal

Congressional Session

119th Congress

Citation Reference

3839, 119th Congress (2025). "EO 14155 Act of 2025". Source: Voter's Right Platform. https://votersright.org/bills/118-hr-3839

Public Opinions

Community submissions related to this bill.

Share your opinion

No public opinions yet. Be the first to submit one for this bill.

Related Bills in Health

HR 3021

Empowering Patient Choice of Medical Care Act

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means

HR 2111

To amend the Federal Food, Drug, and Cosmetic Act to exempt the premium cigar industry from certain regulations.

Referred to the House Committee on Energy and Commerce.

HR 2884

Anti-Racism in Public Health Act of 2025

Referred to the House Committee on Energy and Commerce.

S 1406

SOAR Act of 2025

Read twice and referred to the Committee on Finance.